David Sinclair on Biotech Investing | MOONSHOTS

A lot of biotech companies run out of money. Yeah. It's their number one cause of mortality is capital deficiency.

Yeah, and if the team has a track record of raising money, that's helpful, because there's ways to raise money and then there's ways not to raise money. And if they've never done it, then they can run into trouble. But the team is important because the reputation of the team, everything stems from that. They don't just do a good job and they— your biotech is like a maze that you need to get through. And if you've done it before, you know the way. And there are some wormholes to go quicker. If it's an inexperienced team, let's say it's, you know, a group that just came out of academia, that's quite challenging for them unless they have really good mentors. But also the reputation counts because the money can come in with the reputation of the people. And like you say, without the money, you're not going to get very far.